OncoMatch/Clinical Trials/NCT05277844
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
Is NCT05277844 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies TKI for oligometastatic disease.
Treatment: TKI — A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR driver mutation
Patients with positive oncogene driver mutation (EGFR or ALK/ROS)
Required: ALK driver mutation
Patients with positive oncogene driver mutation (EGFR or ALK/ROS)
Required: ROS1 driver mutation
Patients with positive oncogene driver mutation (EGFR or ALK/ROS)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: tyrosine kinase inhibitor
Patients who have received at least 2-4 months of TKI therapy without progression
Cannot have received: radiation therapy
Patients with prior history of radiation therapy to thorax
Lab requirements
Blood counts
ANC ≥ 500 cells/mm3; Platelets ≥ 50,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl (Use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable)
Adequate end-organ function CBC/differential obtained within 15 days prior to registration on study, with adequate bone marrow function defined as follows: Absolute neutrophil count (ANC) ≥ 500 cells/mm3; Platelets ≥ 50,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl (Use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05277844 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR driver mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK driver mutation is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 driver mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify